Valion Bio
VBIO
3 hedge funds and large institutions have $83.8K invested in Valion Bio in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
0.36% more ownership
Funds ownership: 4.22% → 4.58% (+0.36%)
25% less funds holding
Funds holding: 4 → 3 (-1)
25% less capital invested
Capital invested by funds: $112K → $83.8K (-$28.2K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.62K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$391 |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$90 |
VBIO Hedge Fund Activity: Q1 2024 in Review
3 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2024, worth a combined $83.8K — down 25% from $112K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of VBIO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $4.62K. The largest seller was UBS Group, exiting entirely with an estimated $391 sold.
- 3 institutional investors held Valion Bio (VBIO) as of Q1 2024, down from 4 in Q4 2023.
- Funds reported $83.8K of Valion Bio stock for Q1 2024, down 25% quarter-over-quarter.
- 0 funds opened new Valion Bio positions in Q1 2024 and 1 closed out, a net change of -1 holder.
- The largest Valion Bio buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $4.62K added.
- The largest Valion Bio seller in Q1 2024 was UBS Group, an estimated $391 sold.
Based on aggregated 13F filings for Q1 2024.